苯甲酰磺胺噻唑类PTP1B抑制剂的构效关系研究

SAR of benzoyl sulfathiazole derivatives as PTP1B inhibitors

蛋白酪氨酸磷酸酶(protein tyrosine phosphatase,PTP)1B是治疗2型糖尿病(T2DM)及肥胖症的潜在靶点。在前期研究中,基于PTP1B酶的变构抑制位点设计得到了具有体内胰岛素增敏作用的苯甲酰磺胺噻唑类非竞争性PTP1B抑制剂II。本文基于化合物II进行了初步的构效关系研究,共设计合成新化合物13个,其中化合物10具有显著的PTP1B抑制作用,其对人重组PTP1B的半数抑制浓度IC50为3.97μmol·L-1,与化合物II相当。

Protein tyrosine phosphatase （PTP） 1B is a potential target for the treatment of diabetes and obesity. We have previously identified the benzoyl sulfathiazole derivative II as a non-competitive PTP1B inhibitor with in vivo insulin sensitizing effects. Preliminary SAR study on this compound series has been carried out herein, and thirteen new compounds have been designed and synthesized. Among them, compound 10 exhibited potent inhibition against human recombinant PTP1B with the IC 50 value of 3.97 μmol·-L 1, and is comparable to that of compound II.